CELLTHEON SMART™ TECHNOLOGY PLATFORM
The Celltheon SMART™ Platform is a production ready off-the-shelf platform designed to easily express the most difficult proteins. Unlike other expression technologies, the Celltheon SMART™ platform has been built with an exhaustive approach to protein expression engineering, resulting in unprecedented consistency in producing high titer cell lines, regardless of protein complexity. Combined with an exceptional team of bioprocessing experts, Celltheon offers a risk-free solution to the production of any protein of interest.
- No gene amplification
- No expensive clone selection tools
- Stable pools > 2g/L
- Stable clones > 8g/L
- Clones stable for > 120 generations
- High expression regardless of protein complexity
- 2-3 Weeks for Celltheon SMART™ stable pools
- 8-10 weeks for Celltheon SMART™ stable clones
Developed through genetic engineering SUPERCELL™ has been optimized to express the most challenging proteins at high titers and high quality within 3-5 weeks.
Novel biotherapeutic formats are increasingly composed of high molecular weight, glycosylated, and fused proteins. These proteins pose a challenge to the CHO cell’s native protein folding machinery and have a high tendency to misfold, resulting in activation of intracellular stress pathways ultimately leading to quiescence and senescence. Celltheon’s SUPERCELLs™ have been engineered to handle high levels of ER stress and unfolded proteins before quiescence is initiated, resulting in a 2-5-fold increase in difficult to express protein production. Celltheon has tested the SUPERCELL™ technology on a range of classically difficult to express proteins and compared the results head to head with competing, non-engineered CHO cell platforms.
suPRE™ is the first optimized expression element for transient protein expression.
All expression enhancing elements developed to date have relied on increased transcription of mRNA molecules. Due to the protein expression-rate-limiting effects of RNA processing, RNA degradation, and RNAi silencing, titers in the bioprocessing industry have been slow to increase, especially in transient expression. Celltheon has analyzed libraries of post transcriptional regulatory elements and engineered novel, artificial RNA regulatory molecules that improve RNA export, RNA stability, and RNA translation. With Celltheon’s suPRE™ technology, multigram quantities of protein can be generated within weeks from transfection affordably.
CT STABILIZER™ reduces risks during clone selection and improves consistency in early stage pool production with an unprecedented pool stability of > 60 generations and 100% of clones stable for >120 generations.
When producing high levels of recombinant protein, many of the cell intrinsic pathways utilized in antiviral response are activated, resulting in epigenetic silencing of the highest expressing recombinant protein producers in a population. Further, all recombinant protein production cell lines have undergone oncogenic transformation resulting in worrisome levels of genetic plasticity. Overtime these effects manifest as “genetic instability”, resulting in reduced protein expression over the continuous passaging of the cell line. Celltheon’s CT STABILIZER™ is a novel, artificial genetic element that strongly masks the negative effects of instability on productivity. This element to date has resulted in 100% of selected clones from 100+ programs showing < 10% deviation in expression over 60 – 120 generations of continuous cell growth. CT STABILIZER™ technology effectively mitigates the most common problem to CHO cell lines, genetic instability.